- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02904707
Interest of Skin Graft Pellets in the Management of Ulcers Algic (ULCERALGIQUE)
Leg ulcers (UDJ) is defined as a chronic skin wound, lasting for more than 4 to 6 weeks, between the knee and foot, and with no tendency to spontaneous healing.
In 2002, the prevalence of leg ulcers is estimated between 0.5% and 1% of the general population and 3% in subjects over 65 years.
The sex ratio is generally 3 females to 1 male. It is in most cases a complication of vascular disease, usually venous (70 to 90%), then blood (5-15%), mixed (5-10%) and microcirculatory.
In three quarter of cases, the UDJ is a chronic painful wound to the social repercussions (sleep disorders, eating, work stoppages) and major economic (individual and collective costs of absorptions).
The treatment of a chronic wound uses validated techniques for several years as the skin graft in tablets, associated with the etiological treatment.
The latest recommendations HAS implemented to date from 2006 and concerns the management of leg ulcers predominantly venous.
Few articles in the literature address the possibility of an analgesic effect of the transplant pellets in the treatment of chronic ulcers algic.
In 2008, a Swedish article, evaluated pain before and after skin grafting in carriers of leg ulcer patients and feet and showed that there was a reduction in pain post transplant.
We propose to evaluate the analgesic effect of the skin graft in pellet on a patient population having one or more Algic ulcers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Development of the study:
An information note and the non-opposition of the patient will be collected on the first day of hospitalization. The written and signed consent will be recorded in the patient record.
Clinical data will be collected during hospitalization of the patient, respecting his anonymity only initials and year of birth will be made in terms of data that distinguish patients.
The EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
Finally, a pain assessment questionary by NE (Numeric Evaluation) before and after the skin graft pellet, will be filled by a caregiver during an interview with each patient.
Methodology :
Design: open, prospective, single centric (Vascular Medicine Department), Interventional.
The data to be collected are:
The age, sex, weight, height Length of hospitalization, The type of ulcer, the size of the ulcer disease duration of current or ulcers, duration of ulcer disease The graft antecedent, number of grafts placed in the registry, the date of completion of the graft, The evaluation of pain before and after the completion of the graft on EN, The impact of pain on patient's quality of sleep, the type of pain experienced by patients in terms of their ulcers
The type and number of analgesics taken by patients:
- Antiepileptic therapy (pregabapentine, gabapentin)
- Analgesic treatment to alleviate I (paracetamol), to overcome II (codeine paracetamol, Lamaline, tramadol, nefopam, Ixprim), and compensate III (morphine, opiates).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ile-de-France
-
Paris, Ile-de-France, France, 75014
- Groupe hospitalier Paris saint Joseph
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Inpatient consecutively
- over 18 years old, man, woman,
- having one or more ulcers of venous, arterial or microcirculatory
- for more than four to six weeks
- answering yes to the question: is it painful ulcer?
- consultant in vascular medicine department of St. Joseph hospital in February the month of April 2015
Exclusion Criteria:
- Patients minors
- Patients with dementia
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Questionary EQ-5D
The EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives. Finally, a pain assessment questionnaire by Numeric Evaluation Scale before and after the skin graft pellet, will be filled by a caregiver during an interview with each patient. |
In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of change of pain by Numeric Evaluation Scale
Time Frame: Day -1, Day 1 and Day 7
|
A pain assessment questionnaire by Numeric Evaluation Scale NE (pain rating scale measuring pain intensity from 0 to 10) before and after the skin graft pellet, will be filled by a caregiver during an interview with each patient
|
Day -1, Day 1 and Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of change of the impact of painful ulcers usin EQ-5D Questionary
Time Frame: Day -1, Day 1 and Day 7
|
The EQ-5D questionnaire will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
|
Day -1, Day 1 and Day 7
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ULCERALGIQUE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcer, Leg
-
Nantes University HospitalCompletedHypertensive Leg UlcerFrance
-
University Hospital, Strasbourg, FranceTerminated
-
Assistance Publique - Hôpitaux de ParisCompletedMARTORELL'S ULCER | Hypertensive Leg Ulcer | Necrotic AngiodermatitisFrance
-
Pharma 2100WithdrawnArterial Leg UlcerDenmark
-
SoftOx Solutions ASCompletedVenous Leg Ulcer | Chronic Leg UlcerDenmark
-
Piomic Medical AGVenenklinik Bellevue; Kantonsspital Nidwalden; Spital MännedorfCompletedLeg Ulcers Venous | Leg Ulcer Arterial | Leg Ulcer MixedSwitzerland
-
Ahram Canadian UniversityRecruiting
-
Central Hospital, Nancy, FranceUnknownArteritic Leg Ulcer
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
Clinical Trials on Questionary EQ-5D
-
Cairo UniversityEnrolling by invitation
-
Vascutek Ltd.Active, not recruitingAortic Dissection | Aortic Aneurysm, Thoracic | Aortic Rupture | Penetrating Aortic Ulcer | Acute Aortic DissectionGermany, Canada, Italy, Netherlands
-
Hamilton Health Sciences CorporationRecruiting
-
University Medical Center GroningenUnknown
-
Barts & The London NHS TrustUniversity College, LondonNot yet recruitingQuality of Life | Ventricular Tachycardia | ICD
-
Seoul National University HospitalUnknownScleroderma, SystemicKorea, Republic of
-
University of LiegeCompletedCritical Illness | Covid19 | Psychological Stress | FamilyBelgium
-
RenJi HospitalNot yet recruitingLocalized Prostate Cancer
-
GlaxoSmithKlineCompletedProstatic HyperplasiaUnited Kingdom
-
Chinese University of Hong KongUnknownCOVID-19 | Quality of Life